Background: Cyclopropyl-methoxycarbonyl metomidate, or ABP-700, is a second generation analogue of etomidate, developed to retain etomidate's beneficial haemodynamic and respiratory profile but diminishing its suppression of the adrenocortical axis. The objective of this study was to characterise the safety and efficacy of 30-min continuous infusions of ABP-700, and to assess its effect on haemodynamics and the adrenocortical response in healthy human volunteers.
and clinical research settings, etomidate showed remarkable haemodynamic and respiratory stability, 3, 4 and a quick onset of anaesthesia with a swift recovery. 5 However, etomidate causes significant suppression of adrenocortical steroid synthesis by inhibiting the cytochrome P450 enzyme 11b-hydroxylase, causing prolonged adrenal suppression lasting 6e8 h in patients receiving a single bolus of etomidate and more than 24 h after a continuous infusion. 6e11 This suppression of the adrenocortical axis is especially severe in critically ill patients. 12e14 Nevertheless, etomidate is still used as a single bolus induction agent because of its beneficial cardiovascular and respiratory profile. 15 ABP-700 was created along with a number of other new so-called 'soft-analogues' of etomidate with the aim of retaining its beneficial effect vs side effect profile while diminishing its adrenal suppressive action. 16, 17 Of these soft etomidate analogues, ABP-700 showed the most favourable pharmacology in vitro. 18, 19 Studies in dogs showed that ABP-700 has rapid metabolism and that recovery from the hypnotic effect is quick, and adrenocortical responsiveness was not significantly different from that after a propofol infusion. 1 Recently, a first-in-man, bolus-only study of ABP-700 was conducted, 20 in which ABP-700 showed a rapid onset of anaesthesia/sedation with rapid recovery. Stimulation with adrenocorticotropic hormone (ACTH) caused a physiological cortisol response in all subjects comparable with that seen in placebo subjects. An adverse event (AE) frequently observed in that study was dose-related involuntary muscle movement (36 of 50 volunteers receiving ABP-700). Tachycardia (13 out of 50 volunteers receiving ABP-700) and tachypnoea (13 of 50 volunteers receiving ABP-700) were also frequently observed AEs. 20 Here we present the results of a Phase 1 randomised, single-blind, placebo-and propofol-controlled study in healthy human volunteers to assess safety, tolerability, and clinical effect of single ascending, 30 min i.v. infusion doses of ABP-700. Our goal was to characterise the safety and efficacy of ABP-700 and to assess its effect on haemodynamics and the adrenocortical axis. The effects of premedication with fentanyl 1 mg kg À1 , in addition to ABP-700 50 mg kg À1 min À1 , were also studied.
Methods
This was a single-centre, single-blind, randomised, placeboand propofol-controlled study. A detailed description of the methods can be found in the first-in-man, bolus-only study of ABP-700. 20 Here we provide a brief overview of study subjects, study execution, assessments, and data recording. 
Study management and registration

Subjects
Healthy (ASA physical status I), non-smoking men and women aged 18e45 yr were eligible for this study. Women were only included if they were of strict non-childbearing potential. Subjects were excluded if they had received ABP-700 in a previous study.
Study execution
Subjects were required to visit the clinical pharmacology unit (CPU) thrice: a screening visit, a 2-day and night admission to the CPU (within 28 days of the screening visit) during which study treatment was administered, and a follow-up visit within 4e6 days after study drug administration. A consultant anaesthetist was present throughout the conduct of the study until full recovery of the subject. After each cohort, all available data regarding safety, tolerability, PK, and PD were evaluated by the principal investigator (PI), the sponsor, and the ethics committee before proceeding to the next dose. Stopping criteria for further drug escalation were identical to the single-bolus study 20 : Grade 3 or higher dose-limiting toxicity event as defined in the September 2007 Food and Drug Administration Guidance; local injection site reactions that were Grade 2 or higher; bradycardia considered clinically significant; and QTcF (QT interval corrected according to Fridericia) change from baseline >100 ms or total QTcF of >500 ms; SpO 2 <90% not resolved by simple stimulation, jaw thrust, or supplemental oxygen administered via nasal prongs; any serious AEs that were considered by the PI to be related to the study drug; and any clinically significant AEs that the sponsor and PI considered a safety concern.
Assessments
AEs were evaluated according to the Medical Dictionary for Regulatory Activities (MedDRA: version 16.0) throughout the study period. Safety and tolerability were further assessed through physical examinations, safety laboratory tests (serum chemistry, haematology, arterial blood gas, urinalysis, and coagulation assessments) before, during, and after drug dosing, temperature measurements and infusion site reaction monitoring. Intermittent 12-lead ECGs were examined for changes in PR, QRS, and QTcF intervals. Haemodynamic and respiratory stability was monitored continuously through a Philips MP50 monitor (Philips, Eindhoven, The Netherlands) with a high frequency sampling rate of 0.2 Hz. Clinical signs of upper airway obstruction and respiration were observed and documented by the attending anaesthetist.
Arterial blood gas values were obtained before dosing and 30 and 60 min after the start of the infusion.
Adrenal function was assessed by monitoring plasma cortisol before and after an ACTH stimulation test in which synthetic ACTH 250 mg [Cortrosyn
Pharmaceuticals, Rancho Cucamonga, CA, USA] was administered by i.v. bolus 60 min after stopping ABP-700 infusion. Baseline cortisol concentrations were obtained before 9:00 am and were later measured 60 and 120 min after ACTH stimulation.
MTD was reached if three or more volunteers within one dosing cohort met stopping criteria.
Depth of sedation, anaesthesia, or both was evaluated using the modified observer's assessment of alertness/sedation (MOAA/S) scale (see Supplementary Digital Content 1). MOAA/ S scoring was performed 1 min before dosing, every 30 s for the first 2 min of infusion of ABP-700, every min until 5 min after the start of the infusion, then every 5 min until termination of the infusion, and finally every 30 s until full recovery of the subject (defined by three consecutive MOAA/S scores of 5). BIS was used to continuously measure drug effect on the bifrontal EEG pattern using the BIS-VISTA ™ monitor (Medtronic, Dublin, Ireland) and bilateral BIS ® Sensor electrodes. BIS values range from 100 to 0, in which lower values demonstrate more drug effect. 22 Based on pre-clinical observations and initial observations, 20 and known properties of the parent compound etomidate, IMM were anticipated. There was no standardised nomenclature or scoring system applied to characterise such movements, as was the case when similar movements were described for etomidate. 23 As such, we performed a post hoc analysis of observed IMM using the same descriptive system used in the previous study of ABP-700 in human volunteers: 'extensive movements' defined as IMM that involve the whole body or a considerable part of it, or 'few movements' defined as IMM that occur in a few body parts, such as the arms bilaterally or the face. Other observations recorded were apnoea (for 20 s or more), tachypnoea (20 rpm or more), sinus tachycardia (heart rate of 100 beats min À1 or more if a clinically significant change from baseline (assessed by the anaesthetist)), hypertension (mean arterial pressure of 110 mm Hg or higher), and desaturation (clinically significant decrease of SpO 2 below 95%). All events had to last >20 s to be deemed clinically significant. Arterial and venous blood samples were also obtained during this study, to analyse the PK of ABP-700; these data will be included in future work on the PK, PD, and PK/PD relationships.
Data recording
A dedicated and validated electronic software package (RUGLOOP II © , Demed, Temse, Belgium) was used to capture data on vital signs, MOAA/S, BIS, comments, and a subset of PK sampling times. Analogue information such as ECG parameters was recorded for further post hoc analysis. Data were validated through visual and computerised methods in order to ensure quality.
Statistics
Sample size was based on previous experience studying safety, efficacy, PD, and PK of new agents. Descriptive statistics are displayed as mean (standard deviation) or geometrical mean (95% confidence interval) unless otherwise indicated.
Results
Subjects
Subjects (233 total) were screened by QPS Netherlands B.V. for participation, and 40 subjects were enrolled. Of the 40 subjects included, 25 received ABP-700, 10 received propofol, and five received placebo. Increases in systolic and diastolic arterial pressure were observed in all cohorts who received ABP-700 ( Fig. 1 ; for individual data see Supplementary Digital Content 4). A small dose-dependent increase in heart rate was observed across the ABP-700 cohorts. The placebo cohort maintained a stable haemodynamic profile, and the propofol cohort showed a slight decrease in heart rate, systolic, and diastolic arterial pressure. After termination of the infusion at 30 min, There were no clinically significant differences in ventilatory frequency between cohorts, although ventilatory frequency was slightly higher with higher doses of ABP-700 ( Fig. 2 and Table 1 , for individual data see Supplementary Digital Content 4). Respiratory pauses were clinically observed in a number of subjects receiving ABP-700, but all such events lasted <20 s and were not deemed clinically significant. Two episodes of true apnoea were recorded in the 60 mg kg À1 min À1 cohort and two in the propofol cohort. In the 60 mg kg À1 min À1 cohort, two subjects received airway support, consisting of chin lift and jaw thrust, to maintain a patent airway. Oxygen saturation fell to <95% in one subject in the 60 mg kg À1 min À1 cohort, who experienced two brief episodes (<5 s) of saturation of 91%. PaCO 2 remained stable in all cohorts.
IMM, initially described as 'muscle twitching' or 'myoclonic activity', were observed in all cohorts receiving ABP-700 (Table 1 ) with higher dosing regimens showing more extensive IMM. We were unable confirm statistically significant dose dependency as our study was underpowered to address this No significant changes were seen in serum chemistry, haematology, urinalysis, or coagulation in any cohort. Serum methanol concentration was below the limit of quantification in all cohorts. There were no significant changes in arterial blood gas parameters between baseline, 30 min post-dose, or 60 min post-dose (Supplementary Digital Content 6 ). By 12-lead ECG, there were no apparent effects or a linear relationship between changes in any ECG parameter with arterial or venous ABP-700 concentrations. Stopping criteria for further drug escalation were met for one subject in the 60 mg kg À1 min À1 cohort because of tachycardia, tachypnoea, and hypertension. An MTD was not defined. Upon stimulation with ACTH, plasma cortisol concentrations increased by at least 200 nM at 60 and 120 min after ACTH administration in the ABP-700, propofol, and placebo cohorts, consistent with no adrenal suppression (Fig. 3) . ACTH stimulation tests were not carried out in subjects who received fentanyl as a pretreatment to ABP-700 50 mg kg À1 min À1 , as the ABP-700 dose was the same as a previous cohort.
Clinical effect
All cohorts that received ABP-700 showed a rapid decrease in BIS values (Fig. 4 , for individual data see Supplementary Digital
Content 4). At 40 mg kg
À1 min À1 and above, BIS fell below 50 within 10 min and reached a stable nadir after 12e15 min. Within 8 min after discontinuation of ABP-700 infusion, BIS returned to baseline values for all cohorts receiving either ABP-700 or propofol. In the propofol cohort, BIS decreased slightly to values around 75. There was no increased EMG activity observed by the BIS monitor in any cohort. Clinical sedation effect, as measured by the MOAA/S scale, was dose-dependent with higher ABP-700 doses associated with both deeper sedation levels and an increased frequency of sedation events (Fig. 5) . In the placebo cohort, no subject showed sedation. In the propofol group, MOAA/S scores between 5 and 3 were observed except for one observation of 2. Onset of deep sedation or anaesthesia was observed from a dose of ABP-700 40 mg kg À1 min À1 and upwards, albeit not in every subject. short lasting upper airway obstruction and a dose-dependent increase in arterial blood pressure and heart rate. No adrenal depression was found in any subject receiving ABP-700. An MTD for ABP-700 during continuous infusion was not identified.
Influence of fentanyl
The haemodynamic profile of a continuous infusion of ABP-700 showed similar characteristics to the first-in man bolus study. 20 There was no ABP-700-induced cardiovascular depression, which is reported in propofol induced anaesthesia. 24 No decrease in systolic or diastolic arterial pressure was observed in the ABP-700 cohorts, and arterial pressures in the ABP-700 groups were higher than in the propofol and placebo groups. A dose-dependent increase in heart rate was observed in cohorts receiving ABP-700. An increase in heart rate with preservation of blood pressure stability during induction has been observed with other anaesthetic agents, such as etomidate, 25 and volatile anaesthetics desflurane 26 and isoflurane. 27 ABP-700 produced a slight increase in ventilatory frequency overall, with some short-lasting decreases that did not appear centrally-induced, but rather as a result of IMM causing shortlasting and self-limiting upper airway obstruction. PaCO 2 values indicate that decreases in ventilatory frequency did not cause significant metabolic alterations because of hypoventilation.
ABP-700 did not cause suppression of the adrenal axis at any infusion dose, showing a minimum of 200 nM increase in plasma cortisol concentrations 60 min and 120 min after stimulation with ACTH. This is in contrast with etomidate, which is more potent as an adrenocortical inhibitor than as a sedative-hypnotic agent. 15 A typical anaesthetic induction dose of etomidate thus represents a massive dose with respect to adrenocortical inhibition. 19 ABP-700 is quickly eliminated because of a rapidly hydrolysed ester bond, and because of this, it was hypothesised that ABP-700 does not produce adrenocortical suppression. This hypothesis is supported by pre-clinical studies 1, 19, 28 the first Phase I study in which ABP-700 was administered as a bolus 20 and now when given as a continuous infusion of 30 min. This observation implies that it is safe, in regard to adrenocortical suppression, to use ABP-700 as a continuous infusion, in contrast to etomidate. However, as this was only a 30-min infusion study, no extrapolation of the adrenocortical suppressive action of ABP-700 when administered over longer time periods can be made. IMM were observed in most subjects who received ABP-700, ranging in severity from a few, twitchy movements in one muscle group to extensive, sometimes myoclonic, movements that involved the whole body. Higher doses showed more extensive IMM. In total, four subjects experienced extensive movements, requiring administration of midazolam to diminish IMM. 1, 21 One of these subjects was discontinued from the study. IMM is a phenomenon associated with various GABA A agonists. 29, 30 It is a well-known side effect of ABP-700's parent compound etomidate during induction of anaesthesia. 31 Early clinical studies of etomidate showed an incidence of myoclonus/IMM in 50e60% of unpremedicated patients who received etomidate. 32, 33 IMM is also observed in the use of propofol 34, 35 and has been observed in novel anaesthetic agents investigated in the past, such as AZD3043 36 and eltanolone. 37 Although quantifying IMM is difficult, Meinck and colleagues 23 reported 'three types of rhythmic motor hyperactivity: tremor, synchronous jerks and irregular clonus.' When seen with propofol, IMM are described as 'seizure-like phenomena'. 35 These descriptions are similar to our observations with ABP-700. It is not the frequency of the movements, but rather the magnitude of IMM that makes such movements undesirable in a clinical setting. The aetiology of these movements is not clear, but several hypotheses exist. Meinck and colleagues 23 did not show spiking EEG activity indicative of an ictal origin of the myoclonus, which was confirmed by Doenicke and colleagues. 21 Kugler and colleagues 38 hypothesise that IMM are possibly caused 'by an unsynchronised onset of drug action at different sites of action within the central nervous system', resulting in transient disinhibition of subcortical excitatory neuronal circuits, leading to IMM. As benzodiazepines and opioids are known to inhibit subcortical neuronal activity, 38 coadministration would cause a more equal rate of depression of subcortical excitatory and cortical inhibitory neuronal activity, thus attenuating IMM. This is consistent with observations in this study and by Doenicke and colleagues. 21 As ABP-700 is an analogue of etomidate and also a GABA A receptor agonist, our hypothesis is that the origin of the IMM observed with both drugs is similar. Investigating the potential nature of the IMM in this family of drugs and the influence of opioids and benzodiazepines in attenuating this phenomenon is effects is unclear. Nevertheless, it seems that some level of responsiveness is still present at lower BIS values for ABP-700, as auditory stimuli are still being perceived and responded to. We hypothesise that a possible explanation of this discrepancy between measured and observed drug effect is an unsynchronised on-and off-set of measures of cerebral drug effect. It is possible that ABP-700 has a cerebral drug effect at different effect sites within the central nervous system at different times because of its seemingly steep PD. This might explain why BIS is low (cerebral drug effect in the frontal lobe) while the volunteer still responds. We did not systematically test for retrograde amnesia, but when we asked volunteers afterwards, they did not remember what had happened during drug infusion. This would be indicative of cerebral drug action at the frontal lobe. However, we measured depth of anaesthesia using only the frontal EEG (BIS), not a full EEG, and as such we do not know the cerebral drug effect at other sites within the central nervous system. Limitations of this study are mostly similar to those reported in the bolus-only study of ABP-700. 20 Assessment of clinical drug effect through the MOAA/S scale is a pragmatic and effective tool, but it does not differentiate between light and deep anaesthesia and is subject to inter-investigator variability. 39 In our study, three different anaesthetists carried out the MOAA/S score, and as such this study is also prone to inter-investigator variability. Furthermore, as shown in this study and in contrast to previous studies, BIS patterns sometimes do not correlate with the clinical drug effect. Therefore, the validity of BIS as measuring-equipment for depth of anaesthesia achieved with ABP-700 is not certain, although it is validated for other GABA A -acting drugs. 40 In conclusion, a 30-min continuous infusion of ABP-700 showed a dose-dependent clinical effect as measured by BIS and MOAA/S, and did not cause severe hypotension or severe respiratory depression. ABP-700 did not cause adrenocortical suppression. ABP-700 caused no serious AEs in the context of this Phase 1 trial. However, the presentation and nature of the IMM, observed for this and other GABA A -ergic hypnotic drugs, is a matter of concern to both clinicians and industry. Shortly before submission of this paper, the study sponsor (The Medicines Company, Parsippany, NJ, USA) decided to discontinue its development programme of ABP-700, which had been in early Phase 2 studies in Europe. 
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